Adma Biologics reported $1.68M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Adma Biologics USD 1.68M 150K Sep/2025
Alnylam Pharmaceuticals USD 44.4M 4.15M Sep/2025
Dynavax Technologies USD 1.64M 2K Sep/2025
Takeda JPY 123.63B 40.49B Dec/2025